A Psychedelic Turning Point: How a Landmark Review Re‑frames Psilocybin’s Role in Treating Addiction

Substance‑use disorders (SUDs) now affect nearly 40 million people worldwide and account for millions of deaths each year, yet the standard therapeutic toolbox—counselling, cognitive‑behavioural therapy, and a handful of pharmacotherapies such as methadone, buprenorphine, naltrexone and acamprosate—still leaves large swaths of patients cycling through relapse and recovery. In opioid‑use disorder, for instance, fewer than half of patients remain in treatment after twelve months, and most experience at least one relapse within three years. Alcohol‑use disorder tells a similarly discouraging story.

Against this backdrop, psychedelics have re‑emerged from decades of regulatory deep‑freeze as potential game‑changers. Psilocybin, the psycho‑active compound in so‑called “magic mushrooms,” has received breakthrough therapy status from the U.S. Food and Drug Administration for treatment‑resistant depression, spurring a broader “psychedelic renaissance.” But does the promise extend to addiction?

A richly detailed systematic review in the June 2025 issue of Neuroscience & Biobehavioral Reviews tackles that question head‑on. Led by Shakila Meshkat and an international team of addiction psychiatrists and neuroscientists, the review sifted through 231 papers, ultimately distilling 16 published studies and 26 registered clinical trials that evaluated psilocybin for alcohol, tobacco, cocaine, opioid and mixed SUDs. The final sample encompassed open‑label trials, observational surveys, one double‑blind randomised controlled trial (RCT) and a pilot fMRI study—collectively representing every modern data set on psilocybin‑assisted therapy for addiction.

Key findings include:

Crucially, no serious adverse events were reported across psychedelic‑dose studies when medical screening and clinical monitoring were in place.

One of the review’s most practical contributions is its comparative lens on dose and context. High (“mystical”) doses of 20–40 mg/70 kg, delivered in carefully structured therapeutic settings with pre‑session preparation and post‑session integration, consistently outperformed both micro‑dosing regimens and unsupervised use.

In the authors’ words, “psilocybin doses that evoke a full psychedelic experience—often described as oceanic boundlessness, ego‑dissolution, or a sense of unity—appear to catalyse psychological insight and behaviour change, especially when psychotherapy harnesses that malleable window.”

Dr Amy C. Reichelt, co‑author of the review and neuroscientist at Western University, captures both the optimism and the caution that undergird the findings:

*“Treatments for substance use disorders represent an unmet need, particularly for those who do not respond to first‑line, conventional treatments. The systematic review evaluated the safety and efficacy of psilocybin in clinical research studies. This synthesis of current published results identified that doses of psilocybin that evoke mystical experiences were generally well tolerated and that significant reductions in reported substance use and increased abstinence rates were observed, particularly when combined with psychotherapy. However, studies involving micro‑dosing or psilocybin without clinical support were less conclusive, highlighting that the therapeutic benefits of psilocybin may become apparent when combined with psychological support programs.”

Her remarks underscore the central thesis: psilocybin is not a silver bullet in isolation but a potent catalyst when embedded in a therapeutic scaffold.

Biologically, psilocybin is a serotonin 2A receptor partial agonist, setting off a cascade of cortical network “resetting” that temporarily loosens rigid patterns of self‑referential thinking—patterns that often underlie addiction. Psychologically, the induced state of heightened emotional plasticity may create an opening for patients to re‑evaluate entrenched behaviours and life narratives.

Couple this neuro‑pharmacological window with targeted counselling—motivational interviewing for alcohol, cognitive‑behavioural relapse‑prevention for tobacco—and you have a synergistic model capable of realigning both brain circuits and personal meaning‑making.

Yet enthusiasm must co‑exist with rigour. Of the 16 included studies, only one met the gold standard of a double‑blind RCT, and sample sizes frequently hovered below 30 participants. The open‑label designs raise the spectre of expectancy effects: participants often sign up because they believe psychedelics will help them.

Moreover, the populations skew white, middle‑class and psychologically stable—far from the heterogeneous reality of community addiction services. Long‑term durability beyond 12–24 months is largely unknown, and micro‑dosing, while trendy, remains empirically murky.

Psilocybin’s Schedule I status in the United States (“no accepted medical use, high abuse potential”) clashes with its clinical trajectory. Oregon’s regulated adult‑use model and Colorado’s supervised healing‑center initiative have leap‑frogged federal policy, creating a patchwork that could either accelerate access or sow confusion.

For clinicians, licensure, malpractice coverage and insurance reimbursement are unresolved. For patients, out‑of‑pocket PAP sessions in the grey market can exceed $10,000, raising equity concerns. Any path to mainstream adoption must tackle training, safety monitoring and affordability in parallel with efficacy.

The new systematic review is neither a final verdict nor a mere academic exercise; it is a directional beacon. By synthesising every shred of modern clinical evidence on psilocybin for addiction, Meshkat, Reichelt and colleagues have reset the risk‑benefit calculus. Psilocybin‑assisted psychotherapy now stands as plausibly efficacious, apparently safe, and mechanistically distinct from existing treatments—an extraordinary trifecta in a field that has seen few breakthroughs since the 1990s advent of buprenorphine.

Policymakers, funders and clinicians face a choice: accelerate responsible research and infrastructure now or risk watching an unregulated marketplace fill the vacuum. For the millions caught in the revolving door of relapse, the answer could not be clearer—or more time‑sensitive.

As Dr Amy Reichelt’s balanced assessment reminds us, psilocybin’s full therapeutic promise “may become apparent when combined with psychological support programs.” The task ahead is to build those programs with scientific integrity, cultural humility and a steadfast commitment to patient wellbeing. Achieve that, and a humble mushroom could help rewrite the narrative of addiction treatment for a generation